Exploratory observational study with Two-year outcomes of early in-hospital evolocumab in acute coronary syndrome patients undergoing coronary artery bypass grafting
In ACS patients undergoing CABG, very-early in-hospital evolocumab plus statins achieved sustained LDL-C lowering and fewer adverse cardiovascular events over two years. Given the retrospective observational design, causal inference is limited and residual confounding cannot be excluded. These findings are hypothesis-generating and require confirmation in randomized trials.
Authors
- Gaetano Contegiacomo
- Vito Margari (ORCID: https://orcid.org/0000-0002-4318-2620)
- Francesco Bartolomucci
- Giuseppe Nasso
- Giacomo Errico
- Claudio Larosa
- Mario Siro Brigiani
- Vincenzo Montemurro
- Giacomo Schinco
- Alfredo Marchese
- Isabella Rosa
- Michele Covelli
- Flavio null Fiore
- Walter null Vignaroli
- Ernesto null Greco
- G Santarpino
- Antongiulio Valenzano
- Giuseppe Speziale
- Maria Antonietta De Mola
Institutions
- Paracelsus Medical University (AT)
- Villa Maria Hospital (UG)
- Magna Graecia University (IT)
- Azienda Ospedaliera G.Rummo (IT)
- European University of Rome (IT)
- Ospedale San Carlo (IT)
- Ospedale L. Bonomo (IT)
- Hospital de Santa Maria (PT)
- University of Reggio Calabria (IT)
Publication Details
- Journal
- Frontiers in Cardiovascular Medicine
- Published
- 2026-03-05
- DOI
- https://doi.org/10.3389/fcvm.2026.1705964
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00